Genentech to bear 840 of Roche job cuts; Novartis can't pay all cash for Alcon stake;

@FiercePharma: Roche cuts 4,800 jobs, shuffles 1,500 more. Report | Follow @FiercePharma

> Genentech says it is preparing to cut 840 workers as part of Roche's overall plan to cut 4,800 jobs and shed another 1,500 via internal moves. Report 

> Novartis will not go for an all-cash deal to clinch the remaining 23 percent stake it does not already own in the eyecare group Alcon, CEO Joe Jimenez (photo) told Reuters, citing Swiss law. News

> Merck's Gardasil vaccine appears effective for preventing anal cancer, members of a U.S. advisory panel said. Article

> Ista Pharmaceuticals said U.S. health regulators granted three years of market exclusivity for its recently approved eye drops. Report

> European pharma companies will face major challenges over the next three years implementing new regulatory legislation and compliance requirements, according to a new report. Story

> There are "many limitations" to how drug safety and effectiveness is monitored and reported in Canada and "vast improvements" are needed, says a new report. News

> Swiss drugmaker Roche wants to sell its Boulder production plant to another company that will use it to supply Roche with the drug compounds produced there. Report

> Pfizer's Wyeth unit downplayed the risks that its Prempro menopause drug could cause breast cancer, a lawyer for a Virginia woman who developed the disease told jurors. Item

Biotech News

 @FierceBiotech: Merck cites "jaw dropping" data on cholesterol blockbuster contender. Story | Follow @FierceBiotech

 @JohnCFierce: Actelion shares red hot after co. merely noted that it is always engaged in routine talks with other companies. Report | Follow @JohnCFierce

> Resverlogix shares crater after cholesterol drug disappoints in PhII. Article 

> Roche drops a bomb on the RNAi field. Item 

> Vernalis spikes troubled V3381 program. Story 

Vaccines News

> New vaccine offers hope in fight against pneumonia, meningtis. News

> Health officials call for universal whooping cough, flu vax adult administration. Article 

> UC Irvine team: Alzheimer's vax shows promise. Report 

> Sanofi's Shantha buyout fails to live up to expectations. Item

Manufacturing News

> Mold, ceiling holes cited in CP Pharma warning. Report

> Sanofi/Shantha vax fix will require WHO requalification. Article

> Vial cracking causes halt in lupus drug trial. Item

> RFID system balances readability, price and data. News 

> Metrics unveils PharmaVision channel for outsourced work. Report 

> USP database to track fakes. Story 

And Finally... Scientists have developed a way of smuggling an anti-cancer drug past the protective blood-brain barrier using a nanocarrier--a tiny capsule specially designed to deliver its anti-cancer drug to the cancer cell. Report

Suggested Articles

Colorado is making a play for a Japanese CDMO in hopes it will invest about $100 million in an empty AstraZeneca plant in Boulder.

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

The FDA approved Lundbeck's Vyepti, formerly known as eptinezumab, as the first IV therapy to prevent migraines in adults.